Skip to main content

Table 5 Univariate and multivariate analysis results of Grade 2 or higher radiation pneumonitis rate

From: Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system

Variables

Grade 2 ≥ Radiation Pneumonitis

Univariate Analysis

Multivariate Analysis

n

Rates (%)

OR (95%CI)

p-value

OR (95%CI)

p-value

T stage

T1a + T1b

189

13.2

Reference

-

Reference

-

T2a + T2b

86

15.1

1.168 (0.552–2.377)

0.6760

1.381 (0.590–3.121)

0.4485

Histology

Adenocarcinoma

177

15.3

1.553 (0.698–3.817)

0.2902

1.492 (0.608–3.963)

0.3896

SCC

77

10.4

Reference

-

Reference

-

Gender

Female

69

15.9

1.257 (0.567–2.632)

0.5600

1.298 (0.525–3.099)

0.5643

Male

206

13.1

Reference

-

Reference

-

Location

Upper and Middle

160

11.3

Reference

-

Reference

-

Lower

115

17.4

1.661 (0.834–3.329)

0.1481

2.281 (1.042–5.063)

0.0392

BED (10) IC (Gy)

≥90

256

14.5

NE (1.593–NE)

0.0154

NE (1.803–NE)

0.0118

<90

19

0.0

Reference

-

Reference

-

Margins from GTV to PTV (mm)

≥10

151

21.2

6.185 (2.530–18.579)

<0.0001

6.479 (2.558–19.988)

<0.0001

<10

120

4.2

Reference

-

Reference

-

  1. BED biologically effective dose, CI confidence interval, GTV gross tumor volume, HR hazard ratio, IC isocenter, NE not estimable, PTV planning target volume, SCC squamous cell carcinoma
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us